Abstract A86: PTEN-Long and gemcitabine combination treatment as a therapeutic for pancreatic cancer

Abstract

This abstract is also being presented as a short talk in Session 8: Clinical Science Trials. A full abstract is printed in the Proffered Abstracts section (PR14) of the Conference Proceedings. Citation Format: Roshan Ara Ahmed, Benjamin Hopkins, Carmine Palermo, Steve A. Sastra, Zachary Rapp, Ramon Parsons, Kenneth P. Olive. PTEN-Long and gemcitabine combination treatment as a therapeutic for pancreatic cancer. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr A86.

Expression of PTEN‑long nephritis and its effect on renal inflammation

“…Previous studies have demonstrated that PTEN-Long serves pivotal roles in the development and progression of various cancers (13,25,26). A previous study on the treatment of pancreatic cancer have demonstrated that PTEN-Long targeted therapy combined with chemotherapy may significantly extend overall survival in mice model (15). In the clinical study of ccRCC, expression levels of PTEN-Long protein were observed to be significantly reduced in patients with ccRCC, and the reduced level of PTEN-Long protein caused the increased phosphorylation levels of Akt (16).…”

“…PTEN-Long, which is a translational variant of PTEN produced by in-frame alternative translation, has been demonstrated to have similar roles to PTEN in inhibiting the growth of tumors by inhibiting PI3K signaling through a phosphatase-dependent manner (13). Compared with PTEN, PTEN-Long protein contains an additional N-terminal region, which gives it the ability to cross the cell membrane (14), and due to its functions, PTEN-Long has been selected as a therapeutic target for the treatment of pancreatic cancer (15,16). A previous study has demonstrated that expression levels of…”